Safra Kesesi ve Safra Yolları Tümörlerinde Radyoterapinin Yeri
Özet
Safra kesesi ve safra yolları tümörleri, cerrahi rezeksiyonun tek küratif seçenek olduğu ancak lokorejyonel nüks oranlarının yüksek seyrettiği nadir ve agresif malignitelerdir. Bu yüksek nüks oranları, tedavi başarısını ve sağkalımı artırmak amacıyla neoadjuvan ve adjuvan radyoterapi (RT) veya kemoradyoterapi (KRT) uygulamalarını ön plana çıkarmıştır. Yapılan retrospektif çalışmalar ve Faz-2 SWOG-S0809 protokolü, özellikle pozitif cerrahi sınırı olan ya da ileri evre (T2-4, N1) hastalarda adjuvan RT'nin sağkalım sürelerini anlamlı ölçüde uzattığını ve lokal kontrol sağladığını göstermektedir. Benzer şekilde, ameliyat edilemeyen (anrezektabl) lokal ileri evre hastalarda da kemoterapiye RT eklenmesinin sağkalım avantajı sunduğu saptanmıştır. Ancak bu hastalık grubunun nadir görülmesi nedeniyle literatürde geniş ölçekli prospektif çalışma azlığı bulunmakta, RT rejimleri ve standart dozlar konusunda küresel bir konsensüs henüz sağlanamamaktadır. Bu nedenle, hastaların klinik, radyolojik ve patolojik bulgularının cerrahi, medikal onkoloji ve radyasyon onkolojisi uzmanlarından oluşan multidisipliner bir ekip tarafından hasta bazında değerlendirilmesi en optimal tedavi yönetiminin kurgulanması için kritik bir zorunluluktur.
Gallbladder and biliary tract tumors are rare, aggressive malignancies where surgical resection offers the only curative potential, yet locoregional recurrence rates remain significantly high even after surgery. These high recurrence risks underscore the clinical importance of neoadjuvant and adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) to optimize survival outcomes. Retrospective data and the Phase-2 SWOG-S0809 trial demonstrate that adjuvant RT substantially extends survival and enhances local control, particularly in patients with positive surgical margins or node-positive, advanced-stage disease (T2-4, N1). Furthermore, incorporating RT into chemotherapy regimens for unresectable, non-metastatic cases has shown a distinct survival benefit. However, due to the rarity of these tumors, large-scale randomized data are limited, resulting in a lack of global consensus regarding standardized RT regimens and definitive radiation dosages. Consequently, evaluating each patient's clinical, radiological, and pathological findings through a multidisciplinary team—including surgical, medical, and radiation oncology specialists—is crucial to designing optimal, patient-tailored treatment strategies.
Referanslar
Zhu, A.X., et al., Current management of gallbladder carcinoma. Oncologist, 2010. 15(2): p. 168-81.
Rakic, M., et al., Gallbladder cancer. Hepatobiliary Surg Nutr, 2014. 3(5): p. 221-6.
Rashid, A., et al., K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res, 2002. 8(10): p. 3156-63.
Shin, H.R., et al., Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci, 2010. 101(3): p. 579-85.
Jarnagin, W.R., et al., Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer, 2003. 98(8): p. 1689-700.
Bergquist, A. and E. von Seth, Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol, 2015. 29(2): p. 221-32.
Plentz, R.R. and N.P. Malek, Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Pract Res Clin Gastroenterol, 2015. 29(2): p. 245-52.
Kendall, T., et al., Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int, 2019. 39 Suppl 1: p. 7-18.
Valle, J.W., et al., Biliary tract cancer. Lancet, 2021. 397(10272): p. 428-444.
Houry, S., et al., Gallbladder carcinoma: role of radiation therapy. Br J Surg, 1989. 76(5): p. 448-50.
Mahe, M., et al., Primary carcinoma of the gall-bladder: potential for external radiation therapy. Radiother Oncol, 1994. 33(3): p. 204-8.
Lindell, G., et al., Extended operation with or without intraoperative (IORT) and external (EBRT) radiotherapy for gallbladder carcinoma. Hepatogastroenterology, 2003. 50(50): p. 310-4.
Kresl, J.J., et al., Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys, 2002. 52(1): p. 167-75.
Czito, B.G., et al., Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys, 2005. 62(4): p. 1030-4.
Mojica, P., D. Smith, and J. Ellenhorn, Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol, 2007. 96(1): p. 8-13.
Kim, Y., et al., Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Ann Surg Oncol, 2016. 23(9): p. 2998-3008.
Mallick, S., et al., Adjuvant radiotherapy in the treatment of gall bladder carcinoma: What is the current evidence. J Egypt Natl Canc Inst, 2016. 28(1): p. 1-6.
Ben-Josef, E., et al., SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol, 2015. 33(24): p. 2617-22.
Lim, H., et al., Prognostic factors in patients with gallbladder cancer after surgical resection: analysis of 279 operated patients. J Clin Gastroenterol, 2013. 47(5): p. 443-8.
Hong, E.K., et al., Surgical outcome and prognostic factors in patients with gallbladder carcinoma. Korean J Hepatobiliary Pancreat Surg, 2014. 18(4): p. 129-37.
Shroff, R.T., et al., Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol, 2019. 37(12): p. 1015-1027.
Pollom, E.L., et al., Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med, 2017. 6(1): p. 129-141.
Verma, V., et al., Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes. J Natl Compr Canc Netw, 2018. 16(1): p. 59-65.
Bisello, S., et al., Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. Anticancer Res, 2019. 39(6): p. 3095-3100.
Czito, B.G., M.S. Anscher, and C.G. Willett, Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park), 2006. 20(8): p. 873-84; discussion 886-8, 893-5.
Shinohara, E.T., et al., Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys, 2008. 72(5): p. 1495-501.
Liu, M.Y., et al., Stereotactic ablative radiotherapy for patients with unresectable or medically inoperable cholangiocarcinoma. Tumori, 2017. 103(3): p. 236-241.
Gerhards, M.F., et al., Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg, 2003. 27(2): p. 173-9.
Baak, R., et al., Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study. Cancers (Basel), 2021. 13(16).
Hammad, A.Y., et al., Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Ann Surg Oncol, 2016. 23(Suppl 5): p. 912-920.
Park, J., et al., Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver, 2009. 3(4): p. 298-305.
Rizzo, A. and G. Brandi, Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun, 2021. 27: p. 100354.
Sumiyoshi, T., et al., Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. World J Surg, 2018. 42(9): p. 2910-2918.
Rea, D.J., et al., Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg, 2005. 242(3): p. 451-8; discussion 458-61.
Nelson, J.W., et al., Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys, 2009. 73(1): p. 148-53.
